Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $2.6 million.

  • Ernexa Therapeutics' Total Liabilities fell 9510.08% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 9510.08%. This contributed to the annual value of $3.6 million for FY2024, which is 9239.22% down from last year.
  • As of Q3 2025, Ernexa Therapeutics' Total Liabilities stood at $2.6 million, which was down 9510.08% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Total Liabilities peaked at $55.0 million during Q2 2024, and registered a low of $2.6 million during Q3 2025.
  • Moreover, its 5-year median value for Total Liabilities was $21.6 million (2021), whereas its average is $25.6 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Total Liabilities surged by 58671.07% in 2024, and later tumbled by 9510.08% in 2025.
  • Ernexa Therapeutics' Total Liabilities (Quarter) stood at $26.4 million in 2021, then tumbled by 61.4% to $10.2 million in 2022, then soared by 361.06% to $46.9 million in 2023, then crashed by 92.39% to $3.6 million in 2024, then fell by 27.07% to $2.6 million in 2025.
  • Its Total Liabilities was $2.6 million in Q3 2025, compared to $3.1 million in Q2 2025 and $11.0 million in Q1 2025.